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Abstract
Several studies suggest a high comorbidity of substance abuse and schizophrenia, associated with
higher frequency of relapse, more positive symptoms and depression, cognitive impairment, poorer
outcome and treatment response. A high incidence of substance abuse is also observed in first-
episode patients. Among patients with substance abuse, the onset precedes the onset of psychosis
of several years in most cases.
All the patients with a first episode of schizophrenia, at first admission to the Psychiatric Service of
Diagnosis and Treatment of Ospedale Maggiore of Milan during the years 1990 to 2004, have been
included in our study.
The clinical evaluation has been obtained considering the following items of Brief Psychiatric Rating
Scale (BPRS): conceptual disorganization, depressed mood, hostility, hallucinations, unusual content
of thought.
The results showed that 34.7% of first-episode schizophrenic patients had a lifetime history of
substance abuse. The age of onset of schizophrenia is significantly lower for drug abusers than for
patients without any type of abuse and for alcohol abusers (p < 0.005). In multi drug abusers,
cannabis resulted the most frequently used (49%), followed by alcohol (13%), and cocaine (4%).
Substance abusers have obtained a significant higher score in "thought disturbance" item (p < 0.005)
and in "hostility" item (p < 0.005) compared to non substance abusers. Non drug abusers showed
lower mean scores of "hostility" item compared to cocaine abusers and multi drug abusers (p <
0.005).
Our findings seem to indicate that substance abuse in the early course of illness determines an
earlier onset of schizophrenia and increases severity of some psychotic symptoms like
"hallucination" and "unusual content of thought". Therefore persons incurring a risk of
schizophrenia may be warned of the possible relation between substances and psychosis and have
to be counselled against the use of them.
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Introduction
A number of studies suggest a high level of comorbidity
between substance abuse and schizophrenia [1-3], and
approximately half of the patients suffering from schizo-
phrenia have also been substance abusers at some point
during their illness [4]. The comorbidity of schizophrenia
and substance abuse is associated with more frequent
relapses, more positive symptoms and depression, cogni-
tive impairment, and a poorer outcome and treatment
response [5-9].
Several hypotheses have been put forward to explain the
relationship between schizophrenia and substance abuse
[8,10-12]: it has been hypothesised that substance abuse
may increase the risk of schizophrenia, at least in vulner-
able individuals [13,14]; the self-medication hypothesis
suggests that patients abuse drugs to alleviate the symp-
toms of psychosis or the debilitating side effects caused by
antipsychotic medications, such as extrapyramidal symp-
toms [15]; and, finally, it could be a merely coincidental
association of two psychiatric disorders that have similar
age peaks in the distribution of onset and prevalence but
without any causal interrelation.
A high incidence of substance abuse is also observed in
first-episode patients [8], among whom the rates of sub-
stance abuse have been found to range from 20% to 30%
[8,16]. In 2001 Sevy and coworkers found that the 23% of
a sample of 118 patients with first-episode schizophrenia
or schizoaffective disorder met the criteria for substance
abuse or dependence disorder [5]. Among patients with
substance abuse or dependence, the onset of substance
abuse precedes the onset of psychosis by several years in
most cases, and only in a minority begins at the time of a
first episode or later [5,17]. Silver and Abboud found that
60% of first-admission schizophrenic patients had started
substance abuse before their first hospitalisation [12].
In a large retrospective study [11], Allebeck observed that
the onset of cannabis abuse preceded the onset of psy-
chotic symptoms by at least one year in 69% of cases, and
Rabinowitz also found that most of their patients had
started substance abuse several years before the onset of
psychosis [18].
Sevy and coworkers observed that alcohol and cannabis
were the main substances for most first-episode patients
[5]. Hambrecht and Hafner found that 13% of a sample
of 232 first-episode schizophrenic patients had a history
of cannabis abuse [2], and Linszen observed that 26% of
a sample of recent-onset schizophrenic patients were can-
nabis abusers [17].
Various data indicate a relationship between cannabis use
and schizophrenia, but its precise nature remains contro-
versial [2,19]. The etiological hypothesis suggests that the
use of cannabis may cause schizophrenia in vulnerable
subjects (genetically or otherwise), makes its own contri-
bution to the risk of becoming schizophrenic [2,19]. The
vulnerability hypothesis is supported by the fact that sub-
stance abuse precedes the onset of psychosis in many
patients, and that substance abusing patients are younger
at the time of onset of schizophrenia. Hambrecht and
Hafner found an earlier onset of psychosis among sub-
stance (mainly cannabis) abusers in one-third of their
schizophrenic patients [8], and similar results have been
found by Linszen [17], Buhler [20] and Maremanni [21].
The aim of this study was to identify the prevalence and
pattern of substance abuse in first-episode schizophrenic
patients, and the relationships between age of onset,
demographic variables, pattern of symptomatology and
other variables. Particular attention was given to cannabis
use in relation to the onset of schizophrenia.
Materials and methods
This study included all of the patients evaluated at the
time of first admission to the Psychiatric Diagnosis and
Treatment Service (SPDC) of Ospedale Maggiore, Milan,
between the years 1990 and 2004 with a first episode of
schizophrenia and comorbidity for substance abuse disor-
der or substance dependence following the DSM-IV-TR
criteria. The patients were retrospectively diagnosed as
being affected by schizophrenia on the basis of the DSM
IV criteria during subsequent hospitalisations or outpa-
tient visits.
A history of drug abuse was obtained from the informa-
tion given by the patients and their relatives: the data con-
cerned the type of abused substance, the age of onset of
drug abuse, the pattern of drug abuse (before, during or
after the onset of schizophrenia). Urine toxicology was
performed if clinically required.
The subjects assessed as having a schizophrenia-like disor-
der and substance abuse upon admission were followed
up during their hospitalisation after discontinuing sub-
stance use in order to confirm the diagnosis of schizo-
phrenia. Subjects with a confirmed diagnosis of
substance-induced psychosis were excluded from the
study; the diagnosis was retrospectively formulated on the
basis of subsequent observations during hospitalisations
or outpatient visits according to the DSM IV criteria.
The study exclusion criteria were a previous diagnosis of
schizophrenia, a previous diagnosis of substance-induced
psychosis, a previous admission to any psychiatric hospi-
tal, steady treatment in any psychiatric service preceding
admission to our SPDC, the taking of clozapine or any
neuroleptic "depot" therapy, lifelong antipsychotic treat-Clinical Practice and Epidemiology in Mental Health 2006, 2:4 http://www.cpementalhealth.com/content/2/1/4
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ment for longer than 12 weeks, and the presence of an
organic brain syndrome or severe mental retardation.
The clinical evaluation took into account the conceptual
disorganisation, depressed mood, hostility, hallucina-
tions and unusual thought content items of the Brief Psy-
chiatric Rating Scale (BPRS) [22], and referred to the first
admission to the ward; the clinical information was retro-
spectively obtained by consulting the medical records.
The data were statistically analysed by means of descrip-
tive methods, analysis of variance (ANOVA), the chi-
squared test, multifactor analysis of variance, Fisher's test
(LSD), and regression analysis (simple regression), using
Statgraphics plus 5 programs (2000 Manugistics, Inc.
USA).
Results
The results of this study indicate that 285 patients with
schizophrenia underwent first admission to the SPDC of
Milan's Ospedale Maggiore between 1990 and 2004: 180
men (62.2%) and 105 women (37.8%). Their mean age ±
SD at the time of the onset of schizophrenic symptoms
was 26.14 ± 6.58 years (range 15–43), and their mean age
at first admission was 27.53 ± 6.44 years (range 15–44).
The mean duration of hospitalisation was 17.4 ± 13.43
years (range 1–108).
Of these first-episode schizophrenic patients, 34.7% had
a lifetime history of substance abuse: the distribution of
the frequency of the schizophrenic patients on the basis of
the presence/absence of substance abuse from 1990 to
2004 is shown in Figure 1. The substance abusers were sig-
nificantly younger (24.99 ± 6.69 vs 26.75 ± 6.45 years) (p
< 0.05). There was a statistically significant difference in
the gender distribution of substance abusers: 18.10% of
the female schizophrenic patients were substance abusers,
as against 44.44% of the male patients (p < 0.0001).
From the clinical point of view, the substance abusers had
significantly higher scores for the "unusual thought con-
tent" item (5.5 ± 1.53 vs 5.0 ± 1.51; p < 0.005) and "hos-
tility" item (3.63 ± 2.16 vs 2.64 ± 1.84; p < 0.005), but
significantly lower scores for the "depressed mood" item
(2.24 ± 1.53 vs 2.71 ± 1.67; p < 0.05) (Fig. 2).
The people who had abused drugs for more than 20 years
had significantly higher scores for the "hallucination"
item than those who had abused drugs for a shorter time
(Fig. 3).
Among the abusers, 44% had taken only one substance
throughout their life, whereas 56% were multi-drug abus-
ers (the lifetime abuse of two or more substances, regard-
less of whether they were taken at the same time). The
Frequency of hospitalized patients with the diagnosis of schizophreniform disease from 1990 to 2004 Figure 1
Frequency of hospitalized patients with the diagnosis of schizophreniform disease from 1990 to 2004.
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substances most frequently used by the single-substance
abusers were cannabis (49%), followed by alcohol (13%)
and cocaine (4%); among the multi-drug abusers, 38.24%
used cannabis and cocaine, 35.29% cannabis and alcohol,
11.76% alcohol and hallucinogens, 5.88% cannabis and
opioids, 5.88% alcohol and opioids, and 2.94% cannabis
and amphetamines. The abuse of opioids and hallucino-
gens has therefore always been associated with another
substance (cannabis or alcohol). Considering the drug
abusers as a whole, cannabis was used by 80% of the
patients, 81% of whom were men and 19% were women.
The distribution of abused substances is shown in Figure
4.
The age of onset of schizophrenia was significantly lower
among the cannabis abusers in comparison with both the
cannabis non-abusers (23.97 ± 6.30 vs 26.75 ± 6.45 years;
p < 0.05) and the alcohol abusers (23.97 ± 6.30 vs 29.84
± 8.43 years; p < 0.05).
The mean age at first admission of cannabis abusers was
significantly lower than that of the non-abusers (25.47 ±
6.10 vs 27.98 ± 6.31 years; p < 0.005), whereas the mean
age at first admission of the alcohol abusers was signifi-
cantly higher than that of both the cannabis non-abusers
(32.46 ± 8.05 vs 27.98 ± 6.31 years; p < 0.005) and canna-
bis abusers (32.46 ± 8.05 vs 25.47 ± 6.10 years; p < 0.005)
(Fig. 5).
The mean "hostility" item scores were significantly differ-
ent between the non-drug abusers, the abusers of only one
substance (cannabis, alcohol or cocaine), and the multi-
drug abusers. In particular, the non-abusers had lower
mean scores than the cocaine and multi- drug abusers
(2.63 ± 1.84 vs 4.25 ± 2.06 and 4.05 ± 2.21; p < 0.005)
(Fig. 6). The mean "depressed mood" scores tended to be
lower among cannabis abusers (1.97 ± 1.27) than among
multi-drug abusers (2.55 ± 1.79), non-abusers (2.70 ±
1.67), alcohol abusers (2.15 ± 1.51) and cocaine abusers
(3.0 ± 1.82) (p ≤ 0.05) (Fig. 6).
In relation to the temporal relationship between sub-
stance abuse and the first schizophrenic symptoms, the
former preceded the onset of schizophrenia in 98.97% of
the cases, and the mean duration of substance abuse
before the first symptoms was 7.07 ± 5.73 years (range 1–
BPRS score in drug-abuser patients vs non drug-abuser Figure 2
BPRS score in drug-abuser patients vs non drug-abuser.
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29). In the remaining 2.03%, substance abuse had begun
at the same time as the appearance of the first clinical
symptoms (± 6 months); all of these cases concerned can-
nabis use.
There was no statistical difference between the patients
with and without a history of substance abuse in terms of
a family history of psychiatric disorders.
The mean duration of hospitalisation was not statistically
different between the substance abusers and non-abusers,
but was significantly longer among the multi-drug abusers
than the single drug abusers (16.03 ± 11.65 vs 23.05 ±
12.34 days; p = 0.006).
Discussion
Our results suggest a high prevalence of substance abuse
(37.4%) in first-episode schizophrenia in a sample of
patients undergoing first admission. This is in line with
published data indicating a 35% lifetime prevalence of
drug abuse among first-episode cases of schizophrenia
[5,20,23,24], and our finding of a higher proportion of
male patients among the substance abusers is also in line
with those of previous studies [5,8,18,24].
As reported in most previous studies [5,8,18,25], the most
frequently abused substance in our first-onset schizo-
phrenic patients was cannabis, followed by alcohol. The
frequency of substance (particularly cannabis) abuse is in
line with recent general population data. The use of can-
nabis seems to be more frequent among young people
[26] and its cannabinoid content has increased enor-
mously over the last 20 years [27]. In a cohort study of
2032 students, Patton found that 66% of the males and
52% of the female participants reported having used can-
nabis at some point, and 75% had started to use cannabis
when they were teeenagers [28]. Similar findings have
been reported by other authors in different countries
[29,30].
Our findings seem to indicate that substance abuse leads
to an earlier onset of schizophrenia as the age at onset of
schizophrenia was significantly lower among the drug
abusers than among the patients without any type of
BPRS score related to the duration of drug abuse Figure 3
BPRS score related to the duration of drug abuse.
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abuse or alcohol abusers. This is in line with the findings
of several previous studies [11,20,31,32].
The start of substance abuse preceded the onset of schizo-
phrenia by several years in most of our patients, which
seems to contradict the self-medication hypothesis. How-
ever, as pointed out by other authors, it is possible that
substance use improves some latent symptoms experi-
enced by the patients before the onset of schizophrenia
[5,11,12].
In line with the observations of Sevy [5] and Andreasson
[32], we did not find any difference in the family histories
of schizophrenic substance abusers or non- abusers. These
purely anamnestic data seem to support an association
between substance abuse and schizophrenia due to
genetic vulnerability, and do not seem to confirm the
observations of McGuire and coworkers who found a par-
ticularly high risk of schizophrenia among the relatives of
probands who developed, or relapsed into, psychosis in
the context of cannabis use [33].
However, the temporal sequence and younger age of
onset in the group of abusers suggest that schizophrenia
onsets may be precipitated by the start of drug abuse, par-
ticularly the abuse of cannabis. One biological explana-
tion of the relationship between cannabis abuse and the
onset of schizophrenia may be found in recent pharmaco-
logical and genetic studies [34-36]. Molecular studies sug-
gest that cannabis can increase mesolimbic dopaminergic
transmission and inhibit glutamatergic release, in line
with current biological theories concerning schizophrenia
Age of onset of schizophrenia in the different diagnostic cate- gories Figure 5
Age of onset of schizophrenia in the different diagnostic cate-
gories.
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[37]. The recently suggested role of the endogenous can-
nabinoid system in schizophrenia unrelated to previous
cannabinoid consumption introduces an additional per-
spective concerning the mechanism underlying cannabis-
associated schizophrenia [38].
Studies of dual-diagnosis patients also suggest that sub-
stance abuse has an effect on symptom presentation. In
comparison with non-abusing schizophrenic patients,
dual-diagnosis patients have been found to be more
depressed, more thought-disordered, and to have more
positive and negative symptoms [39,40].
Our results seem to confirm that substance abuse during
the early course of illness increases the severity of some
psychotic symptoms such as "hallucinations" and "unu-
sual thought content". We found that first-episode
patients with a history of substance abuse have more
thought disturbances, hallucinations and hostility than
those with no such history. Hostility is particularly
increased in patients who abuse cocaine or more than one
substance, possibly as an action of the substances them-
selves favouring or worsening the appearance of psychotic
disorders. There have been suggestions that depressed
individuals are more likely to use cannabis, and that the
consumption of cannabis is associated with an increase in
anxiety, depression and suicide attempts [41]; however,
we found that our cannabis abusing patients tended to be
less depressed, although this may be due to various diffi-
cult-to-investigate variables, such as the duration of abuse,
the time since the substance was last taken, and the
amount of cannabis used.
In conclusion, our study indicates that drug (particularly
cannabis) abuse is frequent among patients with first-epi-
sode schizophrenia, and has a considerable effect on
symptom presentation; it also seems to precipitate the
onset of schizophrenia at an earlier age. These findings,
which are in line with other recently published data,
underline the need to act early on cannabis abuse. People
BPRS score : depressive mood and hostility in the different diagnostic categories Figure 6
BPRS score : depressive mood and hostility in the different diagnostic categories.
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at risk of schizophrenia should be warned of the possible
relationship between cannabis and psychosis, and coun-
selled against the use of cannabis.
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